

Keppra[®]/Keppra XR[®] (levetiracetam) – New warning

- On April 24, 2017, the FDA approved a new *Warning* to the <u>Keppra/Keppra XR (levetiracetam)</u> drug labels regarding anaphylaxis and angioedema.
- Keppra oral tablets, oral solution and <u>injection</u> are FDA-approved for adjunctive therapy in the
 treatment of: partial onset seizures in patients 1 month of age and older with epilepsy, myoclonic
 seizures in patients 12 years of age and older with juvenile myoclonic epilepsy, and primary
 generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized
 epilepsy.
 - Keppra injection is only approved as an alternative when oral administration is temporarily not feasible.
- Keppra XR is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12
 years of age and older with epilepsy.
- Keppra/Keppra XR can cause anaphylaxis or angioedema after the first dose or at any time during treatment.
 - Signs and symptoms in cases reported in the postmarketing setting in patients treated with levetiracetam have included hypotension, hives, rash, respiratory distress, and swelling of the face, lip, mouth, eye, tongue, throat, and feet.
 - In some reported cases, reactions were life-threatening and required emergency treatment.
- If a patient develops signs or symptoms of anaphylaxis or angioedema, Keppra/Keppra XR should be discontinued and the patient should seek immediate medical attention.
- Keppra/Keppra XR should be discontinued permanently if a clear alternative etiology for the reaction cannot be established.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.